Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $10.00.
Several analysts recently commented on BDTX shares. Weiss Ratings upgraded shares of Black Diamond Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating on shares of Black Diamond Therapeutics in a report on Wednesday, April 29th. BTIG Research lifted their price target on shares of Black Diamond Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Wedbush boosted their price target on Black Diamond Therapeutics from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Finally, Jefferies Financial Group upgraded Black Diamond Therapeutics to a “strong-buy” rating in a report on Thursday, April 23rd.
Check Out Our Latest Research Report on Black Diamond Therapeutics
Institutional Inflows and Outflows
Black Diamond Therapeutics Price Performance
Shares of BDTX stock opened at $2.94 on Thursday. The business’s fifty day moving average price is $2.50 and its 200 day moving average price is $2.82. Black Diamond Therapeutics has a 1-year low of $1.68 and a 1-year high of $4.94. The firm has a market capitalization of $168.46 million, a PE ratio of -3.82 and a beta of 3.34.
Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. Equities research analysts expect that Black Diamond Therapeutics will post -0.57 earnings per share for the current fiscal year.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.
The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.
Read More
- Five stocks we like better than Black Diamond Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
